Eligibility for finerenone in real-world patients with diabetes and chronic kidney disease: Insights from the FIDELITY pooled analysis

Eligibility for finerenone in real-world patients with diabetes and chronic kidney disease: Insights from the FIDELITY pooled analysis

Show other versions (1)

Saved in:

Bibliographic Details
Main Authors:	Alberto Esteban-Fernández, Carlos de Blas-Ruiz, Maitane Fernández-Ustoa, Elena Gabaldón-Perucha, Beatriz López-Gómez, Guadalupe Ruiz-Martín
Format:	Article
Language:	English
Published:	Elsevier 2025-06-01
Series:	Nefrología (English Edition)
Online Access:	http://www.sciencedirect.com/science/article/pii/S201325142500094X
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Eligibility for finerenone in real-world patients with diabetes and chronic kidney disease: Insights from the FIDELITY pooled analysis
by: Alberto Esteban-Fernández, et al.
Published: (2025-06-01)

WCN24-432 FINERENONE IN CHINESE PATIENTS WITH TYPE 2 DIABETES AND CHRONIC KIDNEY DISEASE: A FIDELITY ANALYSIS
by: Ping Li, et al.
Published: (2024-04-01)

Effectiveness and safety of finerenone in diabetic kidney disease patients: a real-world observational study from China
by: Jingying Zhou, et al.
Published: (2024-12-01)

WCN25-662 EFFICACY AND SAFETY OF FINERENONE IN PATIENTS WITH NEPHRECTOMY: A FIDELITY SUBANALYSIS
by: Jair Munoz Mendoza, et al.
Published: (2025-02-01)

Finerenone cardiovascular and kidney outcomes by age and sex: FIDELITY post hoc analysis of two phase 3, multicentre, double-blind trials
by: George L Bakris, et al.
Published: (2024-03-01)

WCN25-288 EFFECT OF FINERENONE TREATMENT DISCONTINUATION ON KIDNEY AND CV OUTCOMES IN PATIENTS WITH CKD AND T2D: A FIDELITY SUBANALYSIS
by: Stefan Anker, et al.
Published: (2025-02-01)

Effectiveness of finerenone in Chinese patients with type 2 diabetes mellitus and chronic kidney disease with microalbuminuria: A retrospective real‐world study
by: Yiming Wu, et al.
Published: (2025-06-01)

Efficacy and safety of finerenone in non-diabetic CKD patients: a single-center, real-world, retrospective study
by: Yu Li, et al.
Published: (2025-07-01)

Proteinuria reduction by and safety of finerenone in Chinese patients with CKD without diabetes: a real-world retrospective study
by: Guangting Cong, et al.
Published: (2025-08-01)

Eligibility and GDMT up-titration success in heart failure: A real-world assessment.
by: Annika Weidenhammer, et al.
Published: (2025-01-01)

Finerenone in diabetic kidney disease: a new frontier for slowing disease progression
by: Ibrahim S. Alhomoud, et al.
Published: (2025-06-01)

Finerenone and left ventricular hypertrophy in chronic kidney disease and type 2 diabetes
by: Gerasimos Filippatos, et al.
Published: (2025-02-01)

WCN24-933 Effectiveness and safety of Finerenone in Chinese CKD patients without diabetes mellitus: A real-world retrospective study
by: XINGZHI WANG
Published: (2024-04-01)

Cost-effectiveness of finerenone in chronic kidney disease associated with type 2 diabetes in The Netherlands
by: Sara W. Quist, et al.
Published: (2023-11-01)

Eligibility for faricimab in a real-world diabetic macular oedema population: a cross-sectional study
by: Helena Norberg, et al.
Published: (2025-02-01)

Correction: Cost‑effectiveness of finerenone in chronic kidney disease associated with type 2 diabetes in The Netherlands
by: Sara W. Quist, et al.
Published: (2025-05-01)

Finerenone: a breakthrough mineralocorticoid receptor antagonist for heart failure, diabetes and chronic kidney disease
by: Akshyaya Pradhan, et al.
Published: (2024-12-01)

Focus on Finerenone, a Non-Steroidal MRA in Diabetic Kidney Disease. What Physicians Should Know?
by: Dwaipayan Sarathi CHAKRABORTY, et al.
Published: (2022-03-01)

Psychological profile of infertile couples eligible for in vitro fertilization
by: Diego Ramón Hernández Fernández, et al.
Published: (2024-05-01)

Effect and Safety of Finerenone in Patients with IgA Nephropathy
by: Guo Y, et al.
Published: (2025-07-01)

Association of finerenone with prognosis and safety in diabetic kidney disease patients: an undated meta-analysis based on four RCTs
by: Zixuan Zhang, et al.
Published: (2025-07-01)

Real-World Analysis Evaluating Treatment Eligibility and Outcomes in Patients With AML Receiving Intensive Chemotherapy: Insights From an Underrepresented Population
by: Hasmukh Jain, et al.
Published: (2025-04-01)

Clinical utility and safety of finerenone in patients with heart failure: Rationale and design of FINE registry
by: Gonzalo Luis Alonso Salinas, et al.
Published: (2025-08-01)

Effect of finerenone on urinary protein and inflammatory factor levels in type 2 diabetes mellitus patients with diabetic kidney disease.
by: Jia Song, et al.
Published: (2025-01-01)

Finerenone attenuates downregulation of the kidney GLP-1 receptor and glucagon receptor and cardiac GIP receptor in mice with comorbid diabetes
by: Duc Tin Tran, et al.
Published: (2024-11-01)

Finerenone and Estimated GFR Slope in Type 2 Diabetes and CKD
by: Masayuki Yamanouchi, et al.
Published: (2025-07-01)

Outcome of lung cancer surgery and proportion of lung cancer patients eligible for surgery in five Finnish hospitals in 2018, real world study
by: Ville Paappanen, et al.
Published: (2025-07-01)

A meta-analysis of the effects of finerenone on cardio-renal outcomes in patients with type 2 diabetes mellitus or chronic kidney disease
by: Liu Jing, et al.
Published: (2025-06-01)

Prospects of finerenone use in Russian population of patients with chronic kidney disease and type 2 diabetes. Resolution of multidisciplinary. Advisory board
by: M. V. Shestakova, et al.
Published: (2023-11-01)

A comprehensive examination and analysis of the effectiveness and safety of finerenone for the treatment of diabetic kidney disease: a systematic review and meta-analysis
by: Jianyu Chen, et al.
Published: (2024-12-01)

Efficacy and safety of finerenone in individuals with type 2 diabetes mellitus complicated by diabetic kidney disease: A retrospective observational study
by: Yuji Kawaguchi, et al.
Published: (2024-12-01)

Comparative Efficacy of Finerenone versus Canagliflozin in Patients with Chronic Kidney Disease and Type 2 Diabetes: A Matching-Adjusted Indirect Comparison
by: David Cherney, et al.
Published: (2024-07-01)

FIDELIO study: significance and place of finerenone as nonsteroidal mineralocorticoid receptor antagonist in therapy of patients with chronic kidney disease in type 2 diabetes
by: M. S. Shamkhalova, et al.
Published: (2023-12-01)

Lupus clinical trial eligibility in a real-world setting: results from the British Isles Lupus Assessment Group-Biologics Register (BILAG-BR)
by: Ian N Bruce, et al.
Published: (2021-04-01)

Simulation of Fidelity in Entanglement-Based Networks with Repeater Chains
by: David Pérez Castro, et al.
Published: (2024-12-01)

Director Eligibility: Corporations and AI
by: Daisuke ASAOKA
Published: (2024-11-01)

School Participation in the Community Eligibility Provision Before and After the USDA Eligibility Threshold Policy Change
by: Tatum Dykstra, et al.
Published: (2025-05-01)

Cost-effectiveness of treatment with finerenone in mild to advanced stage chronic kidney disease patients with type 2 diabetes from a societal perspective
by: Maarten J Postma, et al.
Published: (2025-06-01)

Second‐line treatment of hepatocellular carcinoma after sorafenib: Characterizing treatments used over the past 10 years and real‐world eligibility for cabozantinib, regorafenib, and ramucirumab
by: Andrea S. Fung, et al.
Published: (2020-07-01)

Examining equity-related eligibility criteria in clinical trials supporting 2022 US drug approvals.
by: Kathy Sliwinski, et al.
Published: (2025-01-01)